EUVIMEDEUVIMED entdecken
Open Access

Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Retinopathy in Patients With Type 2 Diabetes

Fu-Shun Yen, James Cheng-Chung Wei, Teng-Shun Yu, Yu-Tung Hung, Chih-Cheng Hsu, Chii-Min Hwu

JAMA Network Open · 20.12.2023 · 6 (12) · e2348431

DOI: 10.1001/jamanetworkopen.2023.48431 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 20.12.2023. Verfasst von Fu-Shun Yen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Private practice, Taoyuan, Taiwan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Diabetic Retinopathy, Retinal Diseases, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Diabetic nephropathy and diabetic retinopathy share many similarities in pathophysiological processes. Preclinical studies have shown that sodium-glucose cotransporter 2 inhibitors (SGLT2is) have a protective role in the risk of diabetic retinopathy.

Objective

To compare the risk of sight-threatening retinopathy associated with SGLT2is and other second-line glucose-lowering medications (including pioglitazone, sulfonylureas, and dipeptidyl peptidase-4 inhibitors [DPP-4is]) in patients with type 2 diabetes (T2D). Design, Setting, and Participants This cohort study in Taiwan applied a new-user and active-comparator design. Patient demographic and clinical data were obtained from the National Health Insurance Research Database. Adult patients with newly diagnosed T2D from January 1, 2009, to December 31, 2019, were recruited and followed up until December 31, 2020. Propensity score matching was used to identify pairs of patients treated with SGLT2i vs DPP-4i, SGLT2i vs pioglitazone, and SGLT2i vs sulfonylurea from January 1, 2016, to December 31, 2019. Data were analyzed between August 18, 2022, and May 5, 2023. Exposures Treatment with SGLT2i, DPP-4i, pioglitazone, and sulfonylureas starting on January 1, 2016. Main Outcomes and Measures The main outcome was sight-threatening retinopathy in participants. Cox proportional hazards regression models were used to assess relative hazards of sight-threatening retinopathy between the matched case and control groups.

Results

A total of 3 544 383 patients with newly diagnosed T2D were identified. After 1:1 propensity score matching, 65 930 pairs of patients treated with SGLT2i vs DPP-4i, 93 760 pairs treated with SGLT2i vs pioglitazone, and 42 121 pairs treated with SGLT2i vs sulfonylurea were identified. These matched patients included 236 574 males (58.6%), with a mean (SD) age of 56.9 (11.8) years. In the matched cohorts, SGLT2i had a significantly lower risk of sight-threatening retinopathy than DPP-4i (adjusted hazard ratio [AHR], 0.57; 95% CI, 0.51-0.63), pioglitazone (AHR, 0.75; 95% CI, 0.69-0.81), and sulfonylureas (AHR, 0.62; 95% CI, 0.53-0.71). The Kaplan-Meier curves showed that SGLT2i was associated with a significantly lower cumulative incidence of sight-threatening retinopathy than DPP-4i (3.52 vs 6.13; P < .001), pioglitazone (4.32 vs 5.76; P < .001), and sulfonylureas (2.94 vs 4.67; P < .001). Conclusions and Relevance This cohort study found that SGLT2i was associated with a lower risk of sight-threatening retinopathy compared with DPP-4i, pioglitazone, and sulfonylureas. This finding suggests that SGLT2i may play a role not only in reduced risk of diabetic nephropathy but also in the slow progression of diabetic retinopathy in patients with T2D.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Diabetic RetinopathyRetinal DiseasesSodium-Glucose Transporter 2 InhibitorsAdultHumansMaleMiddle AgedCohort StudiesPioglitazoneSulfonylurea CompoundsAgedFemale

Substanzen

PioglitazoneSulfonylurea CompoundsSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Private practice, Taoyuan, Taiwan.
  • Department of Allergy, Immunology and Rheumatology, Chung Shan Medical University Hospital, Taichung City, Taiwan.
  • Institute of Medicine, Chung Shan Medical University, Taichung City, Taiwan.
  • Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan.
  • Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan.
  • College of Medicine, China Medical University, Taichung, Taiwan.

Zitieren

APA

Yen, F. S., Wei, J. C., Yu, T. S., Hung, Y. T., Hsu, C. C., & Hwu, C. M. (2023). Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Retinopathy in Patients With Type 2 Diabetes. JAMA Network Open, 6(12), e2348431. https://doi.org/10.1001/jamanetworkopen.2023.48431

Vancouver

Yen FS, Wei JC, Yu TS, Hung YT, Hsu CC, Hwu CM. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Retinopathy in Patients With Type 2 Diabetes. JAMA Network Open. 2023;6(12):e2348431. doi:10.1001/jamanetworkopen.2023.48431

BibTeX
@article{Yen2023,
  author = {Yen, Fu-Shun and Wei, James Cheng-Chung and Yu, Teng-Shun and Hung, Yu-Tung and Hsu, Chih-Cheng and Hwu, Chii-Min},
  title = {Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Retinopathy in Patients With Type 2 Diabetes},
  journal = {JAMA Network Open},
  year = {2023},
  volume = {6},
  number = {12},
  pages = {e2348431},
  doi = {10.1001/jamanetworkopen.2023.48431}
}
Kostenlos starten →